Browsing Tag
Ltd.
43 posts
Lilly’s oral GLP-1 pill cuts blood sugar and weight without injections—Here’s what the breakthrough data shows
Lilly’s oral GLP-1 drug orforglipron showed strong A1C and weight loss results in Phase 3—find out how it could change diabetes care worldwide.
Chevron shifts focus with $525m East Texas gas divestment to TG Natural Resources
Chevron sells 70% of East Texas gas assets to TG Natural Resources for $525M, retaining upside while funding Haynesville growth through capital carry.
KKR’s full acquisition of FUJI SOFT signals major shift in IT services sector
KKR is set to fully acquire FUJI SOFT, taking the IT services firm private. Find out what this deal means for investors and Japan’s tech market.
IDC Overseas concludes debt exchange, extends maturity on 9.0% notes to 2030
IDC Overseas restructures debt by exchanging 96.63% of its 9.0% Notes due 2026 for new 9.0% Notes due 2030, securing long-term financial stability.
Maypharm introduces SkinColla: The first recombinant human collagen filler transforming skin rejuvenation
Maypharm Co., Ltd. has unveiled SkinColla, a breakthrough in skin rejuvenation technology that leverages recombinant human collagen filler…
Sungrow unveils iHomeManager: A smart energy management solution for the future
Global energy consumption is at an all-time high, with electricity demand expected to grow by more than 25%…
Kexing Biopharm secures FDA IND approval for GB05, advancing pediatric RSV treatment
Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) has received Investigational New Drug (IND) approval from the United States…
FDA accepts application for LEQEMBI subcutaneous dosing: A step forward in Alzheimer’s care
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted…
Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE
In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S.…
Exicure’s stock explodes 78% overnight – but is the comeback for real?
Shares of biopharmaceutical company Exicure Inc. skyrocketed by 78% in after-hours trading, closing at $2.84. The surge came…